Is it Possible to Screen for Type 2 Diabetes at Day 2 in Gestational Diabetes Mellitus Patients Postpartum?

Overview

Within 6 months of delivery, women who had gestational diabetes mellitus should be screened for type 2 diabetes with a fasting plasma glucose test and/or a 2-h postchallenge glycemia in a 75-g oral glucose tolerance test. However, not all women are screened. The objective of this study is to compare the screening test for type 2 diabetes done at 48 hours post-partum versus 8 weeks post-partum. The investigators want to measure the specificity, sensitivity, false and true predictive values of the screening test at 48 hours post-partum compared to the gold-standard.

Full Title of Study: “Is it Possible to Screen for Type 2 Diabetes at Day 2 Gestational Diabetes Mellitus Postpartum?”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: October 2012

Interventions

  • Procedure: Oral glucose tolerance test
    • Subjects will have the Oral glucose tolerance test 48 hours post-partum and the same test 8 weeks post-partum.

Arms, Groups and Cohorts

  • Oral glucose tolerance test
    • oral glucose tolerance test performed 48 hours post-partum and 8 weeks post-partum.

Clinical Trial Outcome Measures

Primary Measures

  • Oral glucose tolerance test
    • Time Frame: 8 weeks post partum
    • Sensitivity, specificity, true and false predictive values of the oral glucose tolerance test

Secondary Measures

  • Acceptability of screening test
    • Time Frame: 8 weeks post partum
    • Prefered moment to do the screening test (48 hours post partum or 8 weeks post partum)

Participating in This Clinical Trial

Inclusion Criteria

  • Dx of gestational diabetes treated with insulin – To be in post-partum – Delivery of a baby of at least 37 weeks of gestation – Have signed the consent form Exclusion Criteria:

  • History of glucose intolerance of diabetes before the pregnancy – Obstetrical pathology during pregnancy

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Université de Sherbrooke
  • Provider of Information About this Clinical Study
    • Principal Investigator: Jean-Luc Ardilouze, Endocrinologist, researcher – Université de Sherbrooke
  • Overall Official(s)
    • Jean-Luc Ardilouze, MD, PhD, Principal Investigator, Université de Sherbrooke

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.